Generate Biomedicines, Inc. Stock: price and insider trades · United States

This page follows insider dealings at Generate Biomedicines, Inc. as filed with SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 9 filings, from 7 insiders.

Only purchases show up on the open market, 4 purchases in all worth €238k, filed by 4 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €207k from Nally Michael, disclosed on 6 March 2026. The buyers include 2 senior executives, 1 finance chief and 1 chief executive.

The data flag 4 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 226 days ago, on 6 March 2026.

For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 9 filings here. Since 2026, the database holds 4 purchases and no sales by insiders of the company.

Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.